Q3 2024 Incyte Corp Earnings Call
Speaker Change: Greetings and welcome to the Insight Third Quarter Financial Results Conference Colin Webcast. At this time, we'll participate in the listening mode. If anyone wants to require operator assistance, please press star zero under telephone keypad. A question, answer session will follow the formal presentation.
Speaker Change: He may be pleased to question Q at any time by pressing star one on your telephone keypad, and we ask you, please ask one question that we're turned to the Q. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Ben Strain, associated with his president and best relations. Please go ahead Ben.
Ben Strain: Thank you Kevin, good morning and welcome to Insights 3rd Quarter 2020 for earnings conference call
Ben Strain: Before we begin, I encourage everyone to go to the Investors section of our website to find the press release related financial tables and slides that follow today's discussion. On today's call, I'm joined by Erve Pablo Cricciana, who will deliver out for a pair of remarks.
Ben Strain: Barry, Mattio and Steven will also be available for Q&A.
Ben Strain: I would like to point out that we'll be making forward-looking statements which are based on our current.
Ben Strain: Expectations and Beliefs, these statements are subject to certain risks and uncertainties and how actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC Firings for additional detail. I will now hand the crawl over to Erve.
Erve: Thank you, Ben and good morning, everyone. The software of 2020-24 was a very positive, quality for insight with a good commercial performance, FDA Proval of Nick Timbo and progress of our pipeline with several key data results for our clinical programs.
Erve: In Q3, total Revenue is increased by 24% the over-year to 1.1 billion with net product Revenue is growing 23%.
Erve: His gross was driven by the ongoing demand gross for Jacket Fye in Othiroa, which I will highlight in the following slides
Erve: In August, we, along with our partner Sindagst, announced the FDA approval of Nictim Vofor patients with chronic grafts, is Ozee's, after failure of two prior lines of therapy
Erve: Making it the first anti-CSS1R antibody approved to target the inflammation and fibres associated with chronic GVHD
Erve: The facility station dosing and limit polar twist following the FDA's approach of Nick Timbo, we have submitted two smaller biosciences to the FDA for the program.
Erve: Following the potential approval of the new viral sizes, we anticipate launching an Indian Boeing's U.S. in the first quarter of 2025.
Erve: Additionally, the positive pivotal agave to a one-triar resource where recently published in the New England Journal of Medicine.
Erve: Link Timbo was also including in the latest NCC and clinical practice guidelines in oncology for chronic GVHD treatment, both highlighting the significance of this dataset and the transformative potential of NIC Timbo.
Erve: So, SMGF for work-solupting-in-premine pediatrics at the peak-dermatitis was recently filed with the FDA, and we are on track for potential approval in the 7th half of 2025.
Erve: During the quarter, we also provided important clinical updates at SMO with encouraging data for our CDK2 inhibitor in Ovarian and Ando-Metral Cancer, as well as data from the phase 3 trial of retipondimab in SCAC
Erve: At EGV.
Erve: We presented extensive data on both poverty-tenib and work-soluble-tenib-creme, including multiple lead-breaking presentations that shows the potential of this program.
Erve: To enhance treatment options for individuals with immune mediated dermatology conditions such as VTLIGO, Atopic Dhammatitis, I2D90, Suprative and Prairie Gondola Durai.
Erve: Moving to slide 6, and on the date of the thought-quality or commercial performance of JKFI, JKFI network of a newware 731 million up 16% year over year.
Erve: State demanding with 10% reasoned by passion growth across all indications.
Erve: Based on the strengths in demand since during the first 3-4 of 2024, we are raising a Waffudio 2024, Jack Athain, Natrov and the Guidance to a New Ranch of 2.74 to 2.77 billion
Erve: Turning to slide seven and looking at trackified total paid demand by indication during the first nine months of 2022-23 on 2024
Erve: As you can see, unit growth remains robust. May the fibrosis stable your volume with some modest growth in against this quarter, while the most significant growth is seen in polythetemia Vera and Grazer to source disease.
Erve: We expect PV to become the largest contributor for Dracatheil over time, supported by the data from the magic PV study which underscores the benefit of early intervention with Dracatheil and its impact on somebody's free survival
Erve: Moving to Obserwar on slide 8, total Obserwar on net product revenues in the South Quadder, where 179 million up 52% when compared to the same quarter last year.
Erve: In the US, the annual prescription trends for 2022 and 2023 and you have today 24, as shown on the right of the slide 8, we've clicked continued your growth of Opsilua from both Atopic Donatei Tis and Diti LIGO
Erve: During the South Quarter we continue to progress with the launch of Obserroir in Europe, so 20 million in that sales during the South Quarter we are driven by France, we're Obserroir is now a reimbursed and a very deboried in retail pharmacy and from Germany.
Erve: Earlier this month we also achieved approval for a Topic Damatitis and VTLigo in Canada
Speaker Change: On Slide 9, I want to highlight three products that I expected to begin contributing to Robin U in the near term.
Speaker Change: We anticipate that Nick Timvo for Swordline Cronic GVHD, Tapacita Ma for Foli Killer Lampfoma, and Roti Pernlima for SESC, Cool Collectively Generate, 800 Million Or More in Incremental Revenue by 2020.
Speaker Change: We anticipate all three products to be available in 2025 and these incremental sales will be leveraging the current commercial infrastructure used for Montjuvi, Tamezi and Jaka Fye
Speaker Change: As illustrated on flight 10, the three launches anticipated in 2025 will be followed by large opportunities in 2020-26 and 2017, including poverty-tenits, silicate to Amtafa Sita Mad in First Line, DLBCF
Speaker Change: Between 2020-2027 and 2020 we have multiple programs at World Transformative Potential with Delaf for each anticipated in 2025.
Speaker Change: I would now turn the color of the top of the paper.
Speaker Change: Thank you for being with me.
Speaker Change: As we continue to execute our pipeline of numerous potential first or besting class medicines, we remain on track to deliver more than 10 high impact launches by 2030.
Speaker Change: And the next few slides I will highlight the number of this programs.
Speaker Change: We continue to expand the opportunity of Ruxelitnik Creme with additional indications.
Speaker Change: Based on the positive phase 3 data in pediatric heat topic dermatitis, the supplemental NDA was recently filed.
Speaker Change: With a potential approval in 2025, we are excited with the possibility of providing an effective non-storey adult topic of option for the two to three million pediatric patients with AD in the US.
Speaker Change: Following interactions with the FDA, we have finalized a design for the Phase 3 study of Ruxelitnik Cream in patients with mild to moderate, hydrinated super-tiva.
Speaker Change: This study, which will have a primary endpoint of high scores 75, is expected to begin in the first half of 2025 and could represent a new treatment option to the approximately 150,000 patients we mild to moderate HS in the U.S.
Speaker Change: As a reminder, we're currently conducting a Phase 3 study evaluating Ruxelitnik Cream and Patience Report Regional Arrows.
Speaker Change: A chronic skin disorder that presents its multiple firm nodules commonly located on the extensive surfaces of the extremities and that are intensely peridic.
Speaker Change: This pivotal study isn't rolling well, and we are now in track to report results in the first half of 2025 with a potential approval of the service of 2026.
Speaker Change: We know Topical Therapy is currently a proof for PN and approximately 200,000 patients diagnosed in the US. We see this as an important additional option for patients and a significant opportunity for Ruxelitnik Cream.
Speaker Change: As shown in life, 15 were continued to execute a broad development plan for poor Sydney, our oral small molecule, highly selective jack one in Hibber
Speaker Change: Over Sidney is currently being evaluated in phase three studies in Adornada Suprativa, Vittaligo and Perriganogelaris, and in randomized phase two proof of concept studies in asthma and chronic spontaneous or tecaria. We've data for both expected in 2025.
Speaker Change: Bobur Sidney has already shown encouraging efficacy and safety in a randomized phase 2 study involving patients with moderate to severe hotter and higher super-tua, a highly painfully inflammatory condition.
Speaker Change: As a reminder, we report that by week 52, up to 29% of patients achieved the High School 100 response, indicating complete resolution of all symptoms.
Speaker Change: Additionally, Povercyniv demonstrated their rapid and significant reduction in pain, offering the opportunity to transform the current standard of care for this disease.
Speaker Change: The two phase three studies, stop Hs 1 and stop Hs 2 are rolling well. Thanks to the strong phase 2 data and the limited effective treatment options available.
Speaker Change: We expect to have phase three data by early 2025.
Speaker Change: We have refined our guidance for the face to proof of concept study of over-sitnik and chronic spontaneously to carry out and now anticipate data in the first half of 2025.
Speaker Change: C.S.U.S. and Mass-Sold Revent Disease, characterized by hives and severe chronic itching.
Speaker Change: The O'Rectivation on Dormal Mass cells and Basifils leads to increase the air levels of TH-1, TH-2 and TH-17 related cytokines
Speaker Change: We know that Jack 1 inhibition can modulate mass electivation, including degranulation and cytokomproduction, both of which contribute to chronic spontaneous reticaria.
Speaker Change: This randomized double line face to study is being conducted in patients who are inadequate the controlled or have progressed on second generation and to histamines, which represent a potential patient population of over 300,000 patients in the US alone.
Speaker Change: As you can see on slide 16, our updated inflammation of the immunity pipeline continues to evolve.
Speaker Change: Recently, we presented promising data from a Phase 2 study of a Ruxelindive Cream in patients with cutaneous like in plainers. At this time, we do not plan to advance Ruxelindive Cream into a Registration Study for this indication and intend to publish a results of this study in the future.
Speaker Change: For Leicons Clarosis, given the prioritization of other indications and programs, we are not currently planning to advance this indication into a registration of all study.
Speaker Change: As a reminder, 262 and 547 are currently being evaluated in a number of indications and we anticipate data for this studies in the first quarter of 2025.
Speaker Change: Moving to MPNC and Graphics of Social Disease on slide 17
Speaker Change: We highlight here a number of ongoing programs where we have the goal of developing new therapeutic options to build upon the significant impact Jackify has had on patients.
Speaker Change: For Betten Hibbiter, Dosis Collation Zone going, both as Monotherapy and in combination with Rucks' Lettnip.
Speaker Change: As a reminder, we have reported reductions in spilling length and volume, as well as improvements in both symptoms and hemoglobin
Speaker Change: We plan to advance this program into phase 3 development and expect to provide an update later this year
Speaker Change: Additionally, for Zilogasertive, our out-to-enheather, we plan to provide an update later this year, and for Rux Lidney XR, we plan to share the bio-curve-lensy data in early 2025.
Speaker Change: Wilming Drone College of Pipeline on slide 18.
Speaker Change: We continue to build a robust portfolio with increased emphasis on first-in-class and our best-in-class and novel immunocology programs.
Speaker Change: Portfacitemah, we shared positive top-line results from the phase 3 study in patients with follicular lymphoma and we are on track to follow the SNDA with the FDA this year, which could lead to a potential approval in 2025.
Speaker Change: As a reminder, the Phase 3 data for First Line DOBCL, in combination with Oscar Chopp, is expected in the first half of 2025.
Speaker Change: During the asthma conference in September, we shared positive top-line results for the pivotal phase 3 study of RetiFoundlyMap and SCAC.
Speaker Change: But you finally got met the primary endpoint, demonstrating a clinically meaningful 37% reduction in the risk of progression or death with a hasor ratio 0.63
Speaker Change: The study showed that Reddy Favleymap was generally well tolerated and no new safety signals were detected.
Speaker Change: At Esmo, we also shared promising evidence of clinical activity from our potentially first-in-class, small molecule sedicate to inhibitor.
Speaker Change: which demonstrated a number of complete impartial responses as well as table disease in patients with second E1 over expressing tumors, most notably in Ovarian and Endometra Cancer.
Speaker Change: We believe our city-k2 inhibitor could be a foundational therapy for patients with a very encounter, as well as other cycling E1 overexpressant tumor types, and we plan to move aggressively in initiate and registration studies in 2025.
Speaker Change: We will be meeting with FDN to come in months to discuss trial designs.
Speaker Change: As highlighted on this slide, we're considering different designs for the registration of program and we will continue to update you on the regulatory strategy for this program in the coming months.
Speaker Change: In closing, slight 20 shows the summary of the considerable number of milestones across the remainder of 2024 and 2025.
Speaker Change: This milestones will continue the transformation of our pipeline with a strong focus on new molecular entities with a potential to make an indelible impact on patients.
Speaker Change: With that, I would like to turn the call over to Christiana for the financial update.
Christiana: Thank you, Pablo and good morning everyone.
Christiana: Our third quarter results reflect strong commercial execution and continued growth with total revenues of $1.14 billion, up 24% versus the same period last year.
Christiana: Total product revenues of $963 million in Q3 were driven by strong demand growth for Jacopai and Obselura and increased revenue contribution from Onjuvi as a result of the acquisition of who writes to Stathasit Ahmad earlier this year.
Christiana: Total royalty revenues were $157 million up to 20% compared to the third quarter of 2023, driven by increased demand for Jakavian Oluhmian.
Christiana: Turning to Jacobay on slide 24, Jacobay net product revenues were $741 million for the third quarter, reflecting continued demand growth with total demand up 10% year over year, driven by growth in all indications.
Christiana: and a $9 million gross to net favorability as a result of two ups to prior quarter estimates.
Christiana: At the end of Q3, Channel Military was up 2% year over year and stable quarter over quarter and within normal range.
Christiana: Turning now to Opcelurant Slide 25, Net Podacreven News for the third quarter were $139 million, representing a 52% year-over-year increase, driven by growth in new patients' starts and retrieves across both a D&VT-LiGo and the U.S.
Christiana: As well as continued contribution from the commercialization of Hoppenot for Vitelligo in Europe.
Christiana: In the third quarter, Europe contributed to $20 million of Opcelure and Net Products revenues, driven by continued update in Germany, and broader access in France were Opcelure's now reimbursed and available in retail pharmacies.
Christiana: Third quarter net product revenues in France include a $2 million stock built up at wholesalers.
Christiana: Finally, in the third quarter, we made significant progress in including Obsellura on the regional former Middle-Earest in Spain and Italy.
Christiana: Moving on to slide 26 and our operating expenses. Total gap are in the expenses worth $573 million for the third quarter due to the $100 million or milestone payment made to microgenics during the quarter and continued investment in our late stage development assets.
Christiana: Excluding all one-time expenses, ongoing R&D expenses for the third quarter increased 26% compared to the same period in 23. Due to continued investment in our late stage development assets, additional R&D expenses resulting from the Asian acquisition and timing of certain expenses.
Christiana: For the nine months and its September 30, 2024, ongoing out-and-day expenses increased 15% compared to the prior year period, as a result of increased investment in the phase 3 studies of Povocitini Benopcelura.
Christiana: As we wrap up the clinical development of axat lemma, bencerd line chronic GVHD
Christiana: Tazeen Ahmad, Relapse Refractor, Fully Killer, Lim Phonma, and Ready-Frangeur Imam in ACAC and Non-Sport Cell and Cancer, as well as the development activities of this continued programs.
Christiana: We anticipate the reduction in investment in those programs to partially offset the increase investment in other programs, which would allow us to control future R&D expense growth.
Christiana: Moving to his DNA, total gap as DNA expenses were $39 million for the third quarter, representing a 15% year-over-year increase, primarily driven by timing of consumer marketing activities and certain other expenses.
Christiana: For the nine months and it's September 30th, total gap is June A expenses increased 6% year over year.
Christiana: Finally, total ongoing operating expenses for the first nine months of the year increased 11% versus 14% increase in revenues, leading to an increase in operating leverage and margins.
Christiana: Moving on to our guidance for 2024, based on the strong performance of Jacqueline in the first nine months of the year, we're increasing our full year 2024 guidance to a new range of 2.74 to 2.77 billion dollars.
Christiana: We're also updating our full-year guidance for other metallurgy and collogy products to a new range of 310 to 320 million dollars to reflect the first nine months actual demand and the un-savorable impact of foreign exchange rates.
Christiana: In addition, we are updating the full year gap, our integrations to include the 100 million milestone payment to macrogenics.
Christiana: The full year gap are in the guidance is now 2.54 to 2.59 billion dollars which includes $791 billion in one time expenses. We lay to the 691...
Christiana: Million Dollars of Upfront Consideration for the Acquisition of Haitian, and the $100 million milestone payment by Croc Janiks.
Christiana: On going out in the guidance remains unchanged.
Christiana: Finally, we are reiterating a full year 2020 for guidance for Cogs and a DNA.
Speaker Change: Operator that concludes our preparing marks, please give your instructions and open the call to Q&A.
Speaker Change: Certainly, we're now making a video on a question and answer session. As a reminder, we ask you, please ask one question, then return to the queue. If you'd like to be a place into question, please press star one under telephone keypad. One moment please, what we pull for questions.
Speaker Change: Our first question today is coming from Michael Schmidt from Gruginheim. Your line is now live.
Michael Schmidt: Hey guys, good morning, congrats on a great third quarter and next to taking my questions. I had one on Poverset Net just looking ahead to the upcoming phase 3 data in hydrogen it is early next year.
Michael Schmidt: So, beyond top line success, if any thoughts on where you think, where you want efficacy to shake out in order to be competitive with you, my right, other market by logic
Michael Schmidt: Is there a particular placebo-justed, on the fact that you're looking forward to it with the poor sit-knit thanks.
Steven: Michael, it's Steven just taking your question and thank you for the question on HS.
Speaker Change: You know, our feeling is if we replicate the phase two data which was incredibly strong and as Pablo said in his prepared remarks
Speaker Change: that includes the Hiscore 100 of up to 29%.
Speaker Change: and then we'll have an extremely favorable efficacy profile that will really benefit patients with.
Speaker Change: with HS. You couple that with, you know, the other symptomatology, particularly the pain from the lesions and we were able to get in at phase two data set to demonstrate pain relief and that will add to what we think will be a differentiated profile that will really benefit patients.
Speaker Change: Obviously it's hard to predict how phase 3 will read out. The other thing Pablo alluded to in his prepared remarks is extremely good in enrollment on both studies which is probably a testament to the phase 2 data drive in investigators' morning to put patients on this.
Speaker Change: Thank you, next question is coming from Jessica Fye from GP Morgan, your line is not long.
Jessica Fye: Hey there, good morning. Thanks for taking my questions. I have a few on a pipeline. I believe earlier this morning, Novartis announced that longer, fall-up time is needed to determine the regulatory passport for their vet inhibitor.
Jessica Fye: Curious how that impacts at all your thinking and your development strategy for your bet.
Jessica Fye: Can you have a think about the potential development plan for Poverset Mith and Tusics to in CSU and just kind of where you see both molecules best, fitting in the treatment paradigm. Thank you.
Jessica Fye: Yes, good morning, Jess, this is Pablo, let me take the first one, so...
Jessica Fye: Our betting hibiter, as we've presented over the past year, and we will provide an updated this year, we're very happy with the data that we've seen so far. We've seen spleen reduction, peveling reduction, we've seen...
Jessica Fye: Pretty impressive improvement in symptoms. Obviously with the caveats that this is not a randomized blinded data, but very important to fact on symptoms.
Jessica Fye: We believe that there are a ability of our bet inhibitor to be those continuously as opposed to the way Palabracia has to be those with a break of a week every two weeks
Jessica Fye: Could potentially make an important difference in our ability to control symptoms.
Jessica Fye: So our plan remains the same, as I said in my prepare remarks, we'll provide an update on the data before the end of the year, and we intend to advance into a phase three study, and we'll provide details on those designs when we provide an update on the data. So that plan remains the same.
Speaker Change: I'm Paul 262 for CSU
Speaker Change: Both are in different stages in a way. Paul was, you know, is in a randomized phase to study with proof of concept.
Speaker Change: We believe there's a potential for Pova in this indication.
Speaker Change: because of their very strong and inflammatory effect that it has. So we look forward to sharing data and future plans after that.
Speaker Change: 262 is in a randomized phase 2 study with two dose levels at 50 and 150 compared with placebo, and we also initiated a study at a lower dose of 25 milligrams compared with placebo. The idea here is to explore full range of doses for 262 to potentially once we have the results.
Speaker Change: Assuming positive results to be ready for pivotal studies.
Speaker Change: In terms of how both fit, I think the difference here is probably a sequence on how this medicines could potentially be used in patients with CSU. As you know, for a slimy therapy, send to histamine.
Speaker Change: About 50-60% of the patients do not respond to his stomach or progress on his stomach.
Speaker Change: This is a multi-year disease and so patients need a sequence of treatments to be used.
Speaker Change: to see which one controls best the same transport up particular individual. The mechanism is different, but we're sitting as a broad and teflammatory fact.
Speaker Change: 262 is...
Speaker Change: Exquisitely designed to block, you know, MRGPRX2 in mass cells in the skin. So we believe that that's how activity will lead to an excellent safety profile. So once we have data for both programs, we'll share a little bit more how we think those can potentially be sequenced in the treatment paradigm.
Speaker Change: Thank you next question today's coming from Salveen Richter from Goldman Sachs, Robotics, and Alight.
Salveen Richter: Good morning, thank you for taking my questions, just regarding the S.G.N. to Fort Foli. Could you just help us understand?
Salveen Richter: Know how you're thinking about development strategy here when you think about the different mechanisms addressing some of these diseases and how you see the differentiation playing out. Thank you.
Speaker Change: Yeah, so we have two programs that work with S&T, Marc GPRX2 and MRGPRX4, so MRGPRX2.
Speaker Change: is currently being developed.
Speaker Change: In three indications, chronic spontaneous or tecaria, and I just highlighted what we are with that indication. We have an ongoing study with two dose levels versus placebo, 15, 150 on the second study of 25 mid-Aganth versus placebo.
Speaker Change: Once we have all that data, we'll decide next steps for chronic spontaneously terraria. For the other two indications are chronic inducibility carrier, particularly focus on two of those, demographicism and cold inducerity carrier and a topic dermatitis.
Speaker Change: The reason why we like the MRGPRX2 is the target, the external cell activity, you know, just for a cell type, mass cells, but also mass cells specifically in the skin and connective tissues. And we think that should lead to an excellent safety profile and make this perhaps in some of the patients the first.
Speaker Change: Therapy After Patience Progress on Antihist Amince in the case of Orte Careous, Chronicle, TeCareous, for example.
Speaker Change: Good evidence of efficacy together with a very, very clean safety. We think we will make this a very important option for patients at that stage of the disease.
Speaker Change: The Second Program with MRGPRX4, this has been developed in patients with colostatic providers, specifically primary and primary sclerosis and primary sclerosis and colongitis.
Speaker Change: We know that exports are receptor, biolastic and biol salts
Speaker Change: Bying to it, and this is an important way in why this patient's having tractable parietas.
Speaker Change: We are conducting a randomized double blind study in those indications. We'll have dating the first Coro 2021-25, Samus for MRGPX2 program and once we report all the data early next year, we'll give you clarity on the next steps.
Speaker Change: Thank you. Next question is coming from Eric Schmidt from Canterbury, Gerald, your line is now live.
Eric Schmidt: Thanks for taking my question and congrats again on all the updates
Eric Schmidt: Maybe a commercial question from a TO on Obsler on the potential upcoming launch for pediatric A.B. in the second half of next year. How do you think you're doing with regard to formulary access and efforts to ensure reimbursement and what could be a pretty size but more to play next?
Speaker Change: Yes, thanks for the question. On the pediatrics side, we're very excited about the potential for us to bring this new tool to patients, to and 11 years old in AD. The Ahmed need is very clearly there. We have 2 million patients in terms of sizing. They're still cycling.
Speaker Change: Vaseline TCS and TCI's
Speaker Change: and Exterior Remain and the Steremen, a higher met need for us to potentially get into that. In terms of the 2025...
Speaker Change: Formerly covered, we look at the former opposition for the entire absoluta brand for next year. Right now, from the feedback that we're receiving, we're confident that we will have a competitive overall coverage also for next year. And that will include obviously the pediatric indication if we had to come to fruition.
Speaker Change: Thank you. Next question is coming from Kelly Sheet from Jeffrey's Real Life, is not alive.
Speaker Change: Congratulations for taking my questions. Curious for the history trials, Rocks-a-Litton Abacran in the mile order to moderate to each
Speaker Change: What is the rationale for using most stringent primary and important high scores 75 over typical use the high score 50. Thank you.
Speaker Change: Here, Kelly, Steven, thanks for the question. So first of all, there's a lot of unmet need in Malto Moder HS.
Speaker Change: The Founding Mastery, as people with absucing nodules
Speaker Change: of Count of About 3 to 10.
Speaker Change: No Drain Intanels
Speaker Change: And those patients can have a reasonable placebo effect because of the disease phenotype I just described to you.
Speaker Change: So, that's looking at his cost 75.
Speaker Change: will help to control for that. It's a higher end point, a higher bar, obviously, you know, a rest-the-unmet need and hopefully, you know, eliminate a large placebo effect to get it across the finish line. It's agreed with Regulatory Agents season. We're a go-on on the program. Thanks.
Speaker Change: Thank you. Next question today is coming from Matt Phipps, from William Blair, your line is not like.
Matt Phipps: Good morning, thanks for taking my question in the next quarter. I had another question on 262, the clinical trial recently showed the addition of a 25-meg arm to that CSU trial. Can you give us any rationale for that? I assume that is maybe not going to be included in the...
Matt Phipps: Q1 update and also just thinking about the profile here. You guys should be thinking most about, I guess, competing with the recent BTK data as far as another oral or do you look at maybe some of the more effective treatments like the kidney bittersus far as I can see guys.
Speaker Change: Yes, Matt, thank you for the question. So the reason for that 25 is to have to explore the full range of doses.
Speaker Change: As you point out, there's an ongoing study, 50 versus 150 versus placebo. That's the data that we're going to have in the first quarter 2025.
Speaker Change: We decided in the meantime to start his second study with 25 Americans versus Paseba in order to have the full range of doses.
Speaker Change: Explored.
Speaker Change: So if we have positive data and the ongoing study, then we'll be ready with the 25 already running to get to a phase 3 study faster. So that's the idea of the 25-metagram to explore the four range of those 26-2 impatience with CSU.
Speaker Change: Intercept for your fit.
Speaker Change: I mentioned a few times before that...
Speaker Change: We've not necessarily expected to send the same level of efficacy that you may have with a kid down a body. When you complete all mass cells, which is what cannot a body is do, obviously the efficacy is very strong. In our opinion, that counts for the series of side effects that have been well reported.
Speaker Change: I think we'll be decaying, Herveter is a little bit cleaner in terms of safety profile. We think 262, if it shows positive data in CSU, will fit perfectly after unto his domain.
Speaker Change: Once Patience Progressive and Antihistamines, what we expect to be a very clean safety profile, for a very convenient daily pill, will be ideal for those patients before they need to try more aggressive alternatives. So that's what we continue to believe is a perfect fit for two-six-two in CSU.
Speaker Change: Thank you, next question today, it's coming from James Shin from Deutsche Bank Rewire, Israel Live.
James Shin: Thanks for taking our questions. For Russell and him, Creme's HS Phase 3.
James Shin: What time point is the high score 75 being assessed? So I'm looking at the pipeline slide, it shows the approval range starting around mid-27 timeframe. So it's day 3, HFDF for rocks cream, expectant in 26.
James Shin: Petit.
James Shin: F-3 for life.
Speaker Change: Yeah, it's Steven, it's hard to be given much precision beyond what we showed in that for the moment because of, you know, the study has to start in the underway and then see how it enrolls.
Speaker Change: The Endpoint is his call 75 as agreed with Regatory Agencies and we'll update.
Speaker Change: At a more appropriate time and try to give more precision on the endpoint. We expect, given the unmet need, the lack of competition in the space, and the excitement around us that it should enroll well, but we'll see how it goes in a later time.
Speaker Change: Thank you next question today, it's coming from the Comparer from Morgan Stanley, Ovalis Alive.
Speaker Change: Hi, good morning. Thank you for taking your question. So we had one on the oncology pipeline.
Speaker Change: For the Phase 1 data set expected for the Mutant Keller program and also for the Jack 2v 617 programs in 2025.
Speaker Change: Could you help us understand just the scope of those data releases that we could expect to see and how you'll be engaging success for these initial data sets? And if I could squeeze a question in on the base business, for OBSO, could you just give us a sense of how...
Speaker Change: Utilization is tracking in terms of...
Speaker Change: of Tubes Perpatient per year for both 80 and Vittaligoberes. Your last update. Thank you.
Speaker Change: Let me take the first one on the pipeline so...
Speaker Change: The Mutant Color R&B program is ahead of 6-7F. We disclose previously a 6-7F program. This year started in health-level in tears to understand the formulation better, and then we advance into in my fibrosis patients and it's now in patients. But it's a little bit behind Mutant Color R.
Speaker Change: and everybody. We expect both to have meaningful data available next year, but that data will be the best, basically, a fairly large number of patients.
Speaker Change: with single agent, Partica Favillamut and Colour antibody and some of the data also in combination.
Speaker Change: I think it's difficult to start putting numbers around what success looks like. What we've been...
Speaker Change: Consistent about is that what we expect to see in addition to all of you said, dressing some of the science and symptoms of myeloperative neoplasms is to see some evidence of decrease in VAF or a legal reduction with this medicines.
Speaker Change: and we expect that we will have that data next year when we decide that the right time into this close to provide an update.
Speaker Change: On Obserular Utilization for ADA
Speaker Change: For AD, we still see over two tubes for patient period. For Vittilago, we'll be seeing up the cohort that we're following throughout the time to make sure that the cohort is meaningful enough and as well as we follow along enough to a very reliable number.
Speaker Change: On what you see on the prescription side is that the growth rate is actually coming from new patients as well as prefield. So we continue to improve.
Speaker Change: Over Time.
Speaker Change: At the same time, we're increasing the folks on the overall adherence and we have quite exciting programs kicking off this quarter and the first quarter next year to actually put more emphasis on this part of support for our patient population.
Speaker Change: Thank you next question today, is coming from Derek Archerlin from Los Fogos, Reliades and LA.
Derek Archerlin: Hey, good morning and congrats on the quarter. I'm just two quick ones. I just on 262. I just want to know if you've characterized the trip tastes reduction you've seen with the agent in the earlier stage trials.
Derek Archerlin: and then just on the base business, you know, just in terms of what we see with Jackify in the MF market, you know, it looks like you're still driving new patient volumes, just with wondering if that's more share games or just the overall market growing. Thanks.
Speaker Change: Let me take the first one on 262, so we are measuring trip tastes and they're going trials.
Speaker Change: Warda Cossion, I think that the degree of the magnitude of the trip to this reduction that we expect to see is not the same you'll see with the police and a mass cell by using a kid down a body.
Speaker Change: I'm going to say that if you deplete mass cells, regardless of their location, you're going to have particular those in circulation, you're going to have...
Speaker Change: Pedramatic Recentriptace Insurculation.
Speaker Change: Well, we address with 262, is MRGPRX2 in the Massels in the skin, as a result of which the decrease in triptage that we may see, it's not going to be quite as dramatic, but we are measuring that and we will report it.
Speaker Change: Thanks Derek, as far as my process, Marc Agos, Jackify, as we said, continues to grow total patience, increased 4% in my life, but in fact, yes, the overall market is growing. Patients are getting first line, they're starting earlier.
Speaker Change: because now you have multiple agents to go to after-jacrify, and patients are being treated in the second line, third line and even fourth line setting, which we had not seen before.
Speaker Change: Thank you. Next question today is from David Lebowitz, from City Bank Rowan, it's our live.
David Lebowitz: Thank you for taking my question. Just following up on the Jackify question. I know understand that the SFF down in the catastrophic out of Apacosts, I accept our...
David Lebowitz: In the middle, they'll be at their lowest $2,000 for your next year. As that played any role in the uptake in Jack Fye growth in the current quarter, and then looking for a delay to the year, could you outline what type of day we might actually see at ash?
Speaker Change: So I'll take the first question and hand it over to Steven or Pablo
Speaker Change: So, yeah, so, Jackify, well, but we always believe that Medicare part D patients who are cancer patients, the adopoccus should really not be a barrier to use.
Speaker Change: So getting rid of the catastrophic coverage this year for patients on Medicare Part D was a very good thing.
Speaker Change: Going to $2,000 out of pocket next year is a very good thing and especially smoothing over the whole period of time.
Speaker Change: Patience at Parker Netanygiven Month.
Speaker Change: is better, but really the growth.
Speaker Change: That we see is coming from demand and mostly as we've said from Polycythemia Vera, and mostly that's because physicians are starting patients earlier on Jackify and Polycythemia Vera, because of the results largely from magic PV, which demonstrates that patients...
Speaker Change: Will have Thumboses, Pre-Survival Improvements when they start Jackify and when they start Jackify earlier.
Speaker Change: David Steven, unfortunately it's premature to comment on what will be seen at Ash, we have to wait for the acceptance and then we will provide the updated at that point.
Speaker Change: That your next question is coming from Marc Frahm from TD County, your line is now live.
Marc Frahm: Hi, yes, thanks for your big mic questions. Just on 262 back to adding the 25 milligram dose, it can just talk about kind of food.
Marc Frahm: What led to adding that and was it informed it all by the AD trial, which I believe this mark is completed.
Marc Frahm: and over as of over the summer. When you get the data from those different to a global sense CSU,
Speaker Change: You obviously don't necessarily need to match the kit antibodies from an FXC perspective given the potential for safety here. But what is that kind of minimum bar that would justify use of a branded drug after anti-Histemies in your mind?
Speaker Change: Herv
Speaker Change: Yeah, so let me first of all, the decision to start, but it's indeed an United States, or it's part of the ongoing study, but it really is, it told us a separate call or we twenty-five Americans for us as possible. They had nothing to do with any data that we've seen from the program. We made that decision early in the process, very soon after the transaction closed.
Speaker Change: and he was based on our desire to be ready for phase three study as soon as possible once we have data. That decision was made at that time.
Speaker Change: In terms of the bar, look all the patients and their ongoing study, refractor is run to his to me. So basically after that, the question is what's the best option for this patient?
Speaker Change: We believe in that context, obviously showing efficacy over placebo.
Speaker Change: And with what we believe will be an excellent safety profile, will be sufficient for 262 to be the first option after unto his domains in some of the patients with CSU. We remain convinced that that is the right place for this drug to be used as swimming obviously efficacy in the randomized trial.
Speaker Change: Thank you, next question is coming from Brian Aben from RBC Capital Market, July is now live.
Brian Aben: Hey, good morning. Thanks for taking my question and the congrats on the quarter and all the progress. Maybe on the CDK2, I'm curious if there's any updates on the aspects that you're considering as you think about the next steps in pivotal plans into the upcoming FDA meeting and sort of, you know, how you're thinking about the balance between exploring late-line versus maintenance. And then any more color around the companion diagnostic for that drop. Thanks.
Brian Aben: Here, Brian, it's Steven, thanks for the question. So, you know, as Pablo said in his slides, the numerous areas we interested in, but broadly speaking
Brian Aben: The Overeign Cancer Settings divided into a Platinum Refractor and a Platinum Sensor to the Settings, divided by a time period of approximately six months, although that's getting grey in terms of re-treatment.
Brian Aben: and a different unmet needs in each population and we interested in both.
Brian Aben: You saw the data update at Erzmo, you know, we got upwards of an north of a 30% response rate, but the data's still maturing and they may actually be later responders where it may go up. So we really like the profile we've seen, we've done, you know...
Brian Aben: 200 Plus Patients of Dost Range in Work, so we think we're in a very good place to pick both a dose and schedule.
Brian Aben: In the Platinum Refractory of Irinkanza Setin, the potentially two ways of thinking about it, for the US primarily the FIA, one could do a single-armed study in that setin looking at response rate and your belief response to get across the finish line.
Brian Aben: as potential confermentary study and for X-US approvals that will require randomized study in that setting. And as it was on the slide deck that would be against investigated choice chemotherapy of which their numbers, this single agent packed a taxol, Hoppenotic and liposomal doxorubison etc.
Brian Aben: with a time to event endpoint like progression free survival. And we like the profile of the drug there.
Brian Aben: The other setting that's of extreme interest to us and we spoke about it at Esmo quite a lot is the platinum sensitive ovarian cancer setting, particularly where the bassoon amount of maintenance is used.
Brian Aben: and the disease gets a little complicated today because you look at HRD proficient in HR...
Speaker Change: Jefferson Patience in terms of...
Speaker Change: of use of pop inhibitors. But if you just focus on the majority population there, the eight-shot deficient patients, you know, the majority of those are cycling E1 positive. We're doing safety work now with CDK2 and Bev maintenance.
Speaker Change: And that's enormous interest to us. There's need there. We can potentially improve curates, and it would be a pretty simple construct in terms of design. It will be Dev maintenance.
Speaker Change: Plus Cibor versus Beb Manson's Class CDK2, and we're doing it in Abley and Work for that now. That is obviously a longer study and we'll deliver later, but we like the profile of the drag there that we've seen so far in terms of its therapeutic ratio. So those are the areas of interest in terms of study designs.
Speaker Change: On the Companion Diagnostic, we haven't given details per se on what our cutoff is.
Speaker Change: But there's two ways of looking again at this population. You can look at the gene in terms of amplification, the CCNE1 gene, and others are doing that. Or you can look at protein of expression by IITC, Sarkin E1 expression, and that's where we focus.
Speaker Change: And that is a much bigger population. With Alcatel, it's probably more than half of ovarian cancer right now.
Speaker Change: But we need to have more discussions with regulators and CDH on our companion diagnostic and the cutoff we're using. But the data we showed at ESMO was using our assay with the cutoff that we've determined internally.
Speaker Change: Thank you. Next question is coming from Andrew Berens from Lear Inc. Partners. Your line is now live.
Speaker Change: Hi, this is Emily Shepman on for Andy. So with the upcoming HS readout for Povo, just one question looking ahead to the commercial dynamics.
Speaker Change: So the efficacy looks strong relative to other agents being developed for HS even though it's oral. I was wondering how you see the safety of POVO and if the JAK class concerns are reflected on the label, how might that impact the drug commercially? I guess I'm asking if you anticipate a black box like other JAK agents.
Speaker Change: Thanks.
Speaker Change: Yes, Steven, I'll address that. I mean, we've spoken a bit about, you know, how well the studies are going. The Phase 2 profile we saw with the HISCO 100 upwards of 29 percent.
Speaker Change: You know, it is an inflammatory disease, so there is a reasonable chance, or more than a reasonable chance, that it will have, you know, class effect labeling in terms of a black box.
Speaker Change: So we do expect that to be the case going forward.
Speaker Change: If you look at the profile of a JAK stat inhibitor versus a biologic which will only attack by definition one pathway, for example IL-17, here we can have more broad coverage of different interleukins.
Speaker Change: And then potentially that would result in better disease control, as we saw in the phase two data. And that's the data set we'd like to replicate. Thanks.
Speaker Change: Thank you. Our next question is coming from Andy Chen from Wolf Research Reliance, now live.
Speaker Change: Good morning, thank you for taking the question. I'm curious if you can remind us the the size of your sales force and how it's split across HIM and DURM and others.
Andy Chen: I'm trying to figure out if your SGNA would trend up as you get your topical into pediatric AD, into PN, and also your JAK inhibitor. Are you going to double down on the derm sales force, or are you going to capitalize on the existing synergies? Thank you.
Speaker Change: In the U.S. and in Canada, we have dermatology, IAI teams.
Speaker Change: and are sized in a way where we anticipate that they will be able to do most of the work required for the launches of the new indication, absolutely clearly, for OBSELOIR. And when POVO comes up, it may be a marginal increase, but nothing that is very, very high. I mean, how many people do you have now in the U.S. material?
Speaker Change: The full footprint across all teams is around a couple of hundred people. We see it in line with other competitors. We also saw competitors staffing up a full field force dedicated to HS.
Speaker Change: We look forward to see the phase 3 data next year, but from what it looks like now, it's going to be a mix of exactly staffing appropriately while capturing synergy with the current footprint we have.
Speaker Change: Thank you. Next question is coming from Jay Olson from Oppenheimer. Your line is now live.
Jay Olson: Oh hey, congrats on the quarter and thank you for taking the question. Since you have a number of catalysts in the near term that could reshape the future top-line growth, can you talk about which one or two catalysts are most important and are there any gaps in your portfolio and how are you thinking about business development strategy over the next year? Thank you.
Speaker Change: Yeah, maybe I'll take that, I mean, so...
Speaker Change: If you go to the slide that we just presented, the slide 10, it's basically saying what has happened recently
Speaker Change: is the, you know, deprobabilization of the increase in probability of success for TAFAR. Nick Timvoo is approved in third line, and Recep Enlimab in SCSE, and as I said,
Speaker Change: I said in my presentation, we...
Speaker Change: Collectively, if you put them together, you end up with something that will be around 800 million. So each of them are.
Speaker Change: Relatively modest, if you want to classify them.
Speaker Change: But when you put them together, this is the meaningful contribution to the top line by 2030. What we have coming soon is POVO, CDK2, Roxolitinib, XR, and Tafacitamab in first-line DL-BCL. So that, again...
Speaker Change: a number of projects where the probability of success has increased with recent events. I mean, for CDK2 clearly the data is good. For Power City Nib,
Speaker Change: 617F, TGF Beta PD-1, all the early pipelines that is moving very well. So what it does to us in terms of business development is really...
Speaker Change: Looking at...
Speaker Change: Maybe early technology type of deals where there are always...
Speaker Change: that we would be interested in, or in the very hypothetical situation where we would find some of that, some very late stage, like commercial product, that would be also of
Speaker Change: quality that we would ask for which is not very common in oncology and dermatology.
Speaker Change: So in some way...
Speaker Change: You know, we are in a position today where our internal pipeline plus the acquisitions that we have done or the busy we have done recently is giving us a portfolio that works very well for what we need to compensate Jessica Fye.
Speaker Change: Patent expiration around 2029 and we are not looking in the very short term at acquiring new assets that would require a lot of R&D expenses and that's why we look at either early or very late with contribution to the top line that will come very quickly.
Jessica Fye: Thank you.
Speaker Change: Thank you. Next question is coming from Gavin Clark Gardner from Evercore ISI. Your line is now live.
Speaker Change: Hey guys, thanks for taking the question. Also had one on 262 in CSU. I'm just wondering how many patients are Zolair naive versus experienced in the study and if you think there could be any potential subgroups with greater efficacy such as IgE low patients. Thank you.
Speaker Change: So, thank you for the question. So, we're not going to provide any details on prior therapy in the study other than to say that all patients have refractory to antihistamines.
Speaker Change: In terms of the potential for certain subsets to have better efficacy, I'd rather not speculate at this point in time.
Speaker Change: Obviously, it's a very different mechanism for a result layer, which is, as you know, an anti-GE antibody, as opposed to 2,6,2. They work in a different pathway, but I'd rather not speculate at this point about the results, the future results of the study.
Speaker Change: Thank you. Next question is coming from Evan Segerman from BMO Capital Markets. Your line is now live.
Speaker Change: Thank you. Thank you. Thank you.
Evan Segerman: Hi guys, thank you so much for taking my question. I'm just thinking about the ALF program readout in 4Q. I know you don't want to speculate too much, but maybe comment on kind of your confidence in this readout. Feels like this program has a few ups and downs despite the mechanistic rationale and maybe highlight what gives you this confidence in the update and really in the program overall going forward.
Evan Segerman: Thank you.
Steven: Yeah, Evan, it's Steven. You know, as we've been alluding to over the last year, we've sort of had to go to higher and higher doses to try and achieve the desired
Steven: effect of the program which, just to remind you, would work potentially through inhibiting hepcidin and then relieving that break so that iron gets released and patient's hemoglobin improves from the underlying disease and then potentially from drug-induced disease.
Steven: And I think it's safe to say at this point in time, you know, we haven't seen to date yet...
Steven: sufficient efficacy to trigger a go on on a future registration program. We'll update more data at the end of the year at an appropriate meeting and give you more color on that. Just to remind you that we do have an ongoing program in FOP that continues to enroll with L2. Thanks.
Speaker Change: Thank you. Next question is coming from Tazeen Ahmad from Bank of America. Your line is now live.
Tazeen Ahmad: Hi, thanks for taking my question. As you think about the H.S. opportunity, can you clarify for us how you think it would be different for RUX Cream
Tazeen Ahmad: versus Povo. And also do you have a sense, I know it's still a little bit early, but
Speaker Change: In terms of usage of tubes for Rux cream and HF, how do you think that will compare relative to what...
Speaker Change: you have seen so far for AD and vitiligo. Thanks.
Speaker Change: As I said earlier, the absence nodule count is limited to less than 10. To get on to our particular study, you have to have 3 to 10.
Speaker Change: And they're approximately up to between 100,000 and 150,000 patients with this.
Speaker Change: with a lot of unmet need.
Speaker Change: These patients tend to be underdiagnosed in the setting and tend to have disease for a long time before getting appropriately diagnosed and seeking treatment, and it may need chronic treatment.
Speaker Change: It's hard to determine now until we conduct the study and get the readouts to exactly how long that would be.
Speaker Change: In terms of povositin, it's looking at the right spectrum of the disease, so the moderate severe population.
Speaker Change: with higher abscess nodule counts with the presence
Speaker Change: from the phase three study readout, but it'll tend to be long therapy if you want to just ballpark it at the moment.
Speaker Change: Thanks.
Speaker Change: Thank you. Next question is coming from Crippa de Veraconda from Truist Securities. Your line is now live.
Speaker Change: Hey guys, thank you so much for taking my question and congrats on the quarter. I have a question about the CDK2 program. I know some of the questions were already answered, but one of your peers just announced the discontinuation of their CDK2 program. I was wondering if you can help us understand how you see the competitive landscape given your data.
Speaker Change: And before you have the conversation with the FDA, or before you move into pivotal trials, should we expect to see any additional data from either ovarian cancer or any of the other indications that you're investigating the drug in? Thank you.
Speaker Change: Thank you.
Speaker Change: Let me take that question. So, in terms of competitive landscape, the competitive landscape for CDK2 is a little bit beyond the mechanism, right? I mean, we think when it comes to ovarian cancer, we are ahead in terms of developing a CDK2 program.
Speaker Change: We disclosed the data, as you know. We have over 200 patients treated. We explored a range of doses. We've seen clear evidence of efficacy and a very, very manageable safety profile. So we intend to start registrational studies next year, which I think that puts us in front when it comes to CDK2 inhibition in ovarian cancer and perhaps also in endometrial cancer. We're doing additional work in other indications.
Speaker Change: Now, the complete landscape is a little bit more complicated than just CDK2 because there's a number of ADCs being developed in ovarian cancer. Obviously, Mervituximab is approved for certain patients with followed receptor alpha expression. There are other ADCs, the same target, as well as additional targets for ADCs.
Speaker Change: I think that the two points I would make is, number one, there isn't complete overlap when it comes to populations, at least not with receptor alpha positive patients. Perhaps for some of the others, the overlap will be a bit more pronounced.
Speaker Change: but
Speaker Change: One of the reasons why we believe that the maintenance, study, and combination of bevacizumab is very important for us in the long run
Speaker Change: molecules such as our CDK2 inhibitor. So while we intend to move aggressively into platinum-resistant patients to get a faster market strategy there, we believe that maintenance will differentiate our CDK2 program, not only from other entrants in the same target, but also against ADCs.
Speaker Change: Thank you. Thank you.
Speaker Change: Thank you. Our final question today is coming from Ren Benjamin from J&P Securities. Your line is now live.
Ren Benjamin: Hey, thanks guys for squeezing me in and congrats on the quarter. I guess just, you know, when we think about the potential for positive phase 3 data from stop HS1 and HS2,
Ren Benjamin: Do you need even, like, longer-term follow-up data, or do you feel that you can file kind of right away? And assuming an approval in 2026...
Ren Benjamin: How do you see this being used, you know, in relation to, you know, currently approved therapies, and what kind of market share do you think you might ultimately achieve? I know Steven has talked about greater than 300,000 patients, but how many patients do you think you might be able to treat?
Speaker Change: So, Ren and Steven, I'll at least do the first part to your question, and obviously we can't speak about a lot of the regulatory aspects, but it is an NDA, a first file-in, so there'll be safety data that'll be needed and we'll, you know, provide updates at the appropriate time, but we continue to guide to a 2026 approval for that at the time. In terms of, you know, it'll be really up to what you see ultimately in terms of the efficacy profile vis-a-vis other orals or biologics in terms of use.
Speaker Change: is between 150,000 to 300,000 patients with this moderate to severe in total, you know, in terms of seeking therapy, potentially, and then, you know,
Speaker Change: The use of biologics versus orals, et cetera, will depend on the profiles of the drugs from the phase three setting.
Speaker Change: Thanks.
Speaker Change: Thank you. We have reached the end of our question and answer session. I'd like to turn the floor back over to Ben for any further closing comments.
Ben Strain: Thank you all for participating in the call today and your questions. The IR team will be available for the rest of the day for follow-up. Thank you and goodbye.
Speaker Change #100: Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.